The Bootstrap Flywheel™
Biotech commercialization does not always move in a straight line from discovery to venture round. The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.
The Flywheel in Practice
Rather than beginning with 'How much money can we raise?', begin with 'What is the smallest high-value milestone we can achieve next?' Each completed milestone should generate new evidence or leverage that expands the company's choices.
- Discovery becomes a defined product hypothesis.
- Customer interviews sharpen the use case.
- A sharper use case improves study design.
- Better studies strengthen IP, regulatory, and partner discussions.
- Stronger evidence improves grant and non-dilutive funding applications.
- Non-dilutive funding creates more evidence without immediate dilution.
- More evidence improves the terms of licensing, partnering, or financing.
Why Momentum Compounds
Commercial credibility is cumulative. A founder who can show a clear use case, stakeholder validation, an IP plan, regulatory thinking, and a milestone-driven budget is easier to fund than a founder presenting science alone. The same is true for strategic partners and university technology-transfer offices.
How to Keep the Flywheel Moving
The flywheel stalls when teams pursue activities that look impressive but do not reduce a meaningful risk. Every major expenditure should be connected to a specific question and a specific future decision.
- What uncertainty does this activity reduce?
- Who will care about the answer?
- What milestone follows if the result is positive?
- Does the work improve financing, licensing, regulatory, or market options?
BYB Takeaway
The Bootstrap Flywheel™ is about sequencing. Small wins become evidence; evidence becomes credibility; credibility expands funding choices; and better funding choices preserve strategic flexibility.
Build the next milestone to unlock the milestone after it.
